multiple myeloma
Conditions
Interventions
Experimental group:Granulocyte macrophage colony stimulating factor (gm-gsf) 300 was used on + 29, + 36, + 43, + 50 days after transplantation µ g. On + 30 days, + 37 days, + 44 days, + 51 days, 16 mg
Control group:Direct access to maintenance therapy Maintenance therapy: lenalidomide 25mg QD Before transplantation, 28 days, 3 months, 6 months, 9 months, 12 months, 18 months and 24 months after tra
Sponsors
Sichuan Provicial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patient criteria: patients meeting the following criteria were recruited in this clinical trial: (1)Diagnosis of multiple myeloma; (2)Aged 18 to 65 years; (3)Karnofsky score >= 70; (4)Serum total bilirubin = 3 months. 2. Sign the written informed consent before screening.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women and women of childbearing age who are unwilling to take contraceptive measures; 2. Patients with severe dysfunction of important organs or diseases affecting the prognosis of treatment; 3. Combined with other uncontrollable diseases that may restrict patients to participate in the trial; 4. People with mental disorders / unable to obtain informed consent; 5. Drug addicts and long-term alcoholics affected the evaluation of the test results; 6. The researcher decided that it was not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;2 years overall survival;Safety; | — |
Countries
China
Contacts
Public ContactChe Feifei
Sichuan Provicial People's Hospital
Outcome results
None listed